See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

The World's First Diabetes Emergency Kit

Gillian Miller - Diabetes and More

The World's First Diabetes Emergency Kit

Todd speaks about Levemir

Todd Hobbs

Todd speaks about Levemir

Close Encounter - A Profile of a Diabetes Patient and Business Insider

Kelly Close

Close Encounter - A Profile of a Diabetes Patient and Business Insider

Actos Archives

Diabetes and Actos

Updated 15 weeks ago
New Type 2 Drugs Change Treatment Decisions

Metformin, the cornerstone in treating type 2 diabetes, saw an increase in usage among type 2s from 23 percent of that population in 1997 to 53 percent in 2012. But that increase has since plateaued due to the introduction of additional drugs that target insulin secretion and glucose regulation.

Comments 0 comments - Jan 4, 2014 - * * * * *

Diabetes Patients on Insulin Sensitizers Run Lower PAD Risk

Insulin sensitizers--drugs that increase sensitivity to insulin such as Avandia and Actos--could help lessen the risk of peripheral arterial disease (PAD) for those with type 2 diabetes, according to a new study.

Comments 1 comment - Jul 5, 2013 - * * * * *

FDA Panelists Vote to Ease Up on Avandia

A significant majority-20 of 26 members attending a combined meeting of FDA advisory committees-has voted to modify or remove the current restrictive label and distribution regulations affecting the type 2 drug Avandia.

Comments 0 comments - Jun 9, 2013 - * * * * *

US Sale of Generic Actos Gets FDA Nod

The Food and Drug Administration has approved US sale of generic pioglitazone (trade name Actos) for the treatment of type 2 diabetes. Actos, originally developed and trademarked by Takeda Pharmaceuticals, works by decreasing insulin resistance in type 2 patients. The prescription drug, which belongs to the class of drugs known as thiazolidinediones (TZDs), has enjoyed great commercial success in the United States since its introduction in 1999, posting estimated sales last year of $2.7 billion.

Comments 0 comments - Aug 27, 2012 - * * * * *

Cheaper Generic Medication for Lipitor, Actos and Plavix

A recent article in the Chicago Tribune reports that patients using Lipitor, Actos, or Plavix may start enjoying savings of up to 90 percent as patents on those drugs expire. The three drugs comprise a significant percentage of the $300 billion brand-name U.S. pharmaceutical market, according to the Tribune.

Comments 2 comments - May 27, 2011 - * * * * *

FDA Significantly Restricts Access to the Diabetes Drug Avandia

The U.S. Food and Drug Administration today announced that it will significantly restrict the use of the diabetes drug Avandia (rosiglitazone) to patients with Type 2 diabetes who cannot control their diabetes on other medications. These new restrictions are in response to data that suggest an elevated risk of cardiovascular events, such as heart attack and stroke, in patients treated with Avandia.

Comments 0 comments - Sep 23, 2010 - * * * * *

ID Genetic Markers That Could Improve Effectiveness of Diabetes Therapies

Scientists have identified five genetic biomarkers that predict how well a type 2 patient will respond to the drug Actos. Their work could be the first step toward a system that would allow doctors to predetermine which drugs will best help each person with diabetes. 

Comments 0 comments - Jul 3, 2009 - * * * * *

Long-Acting Byetta Tops Two Other Diabetes Drugs in Direct Comparison

Results from DURATION-2, a 26-week test comparing the diabetic drugs Januvia, Actos, and experimental long-acting Byetta (Byetta LAR) show that Byetta produced lower A1c's and more weight loss than the other two drugs.

Comments 5 comments - Apr 15, 2009 - * * * * *

Insulin For Type 2 Diabetes: Who, When, And Why?

Physicians who treat people with type 2 diabetes face difficult choices when selecting the best medical therapy for each patient. The decision process is further complicated by the fact that because type 2 diabetes is a progressive disease, therapeutic agents that were initially successful may fail five or ten years later.

Comments 151 comments - Mar 20, 2009 - * * * * *

Women Have Double the Fracture Risk with Avandia and Actos

Avandia (rosiglitazone) and Actos (pioglitazone), two medications used to lower blood sugar in type 2 patients, double the risk of fractures in women, but not in men, says a new study.

Comments 0 comments - Dec 22, 2008 - * * * * *

Next Page »  
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.